AI Governance for Clinical Decision Support: A Compliance Primer

Executive Summary

Clinical decision support tools built on machine learning and, increasingly, generative AI are moving from pilot projects into routine clinical workflows: sepsis prediction, imaging triage, deterioration alerts, clinical documentation assistance, and administrative prior-authorisation support. Very few of these tools were procured through a formal AI governance process, and many healthcare organisations are now running a growing, informally assembled portfolio of clinical AI tools with no single committee, policy, or accountable owner responsible for it as a whole.

That gap is closing from two directions simultaneously. Regulators are moving: the FDA's Software as a Medical Device framework, including its predetermined change control plan pathway for adaptive algorithms, and ONC's HTI-1 rule requiring transparency disclosures for AI embedded in certified health IT, both signal that clinical AI oversight is becoming a defined compliance obligation rather than a voluntary best practice organisations can adopt at their own pace. And the underlying clinical risk is real and specific: a biased, poorly validated, or silently drifting model embedded in a clinical workflow can cause harm at scale and without an obvious signal, long before any individual clinician notices a pattern in their own practice.

This paper sets out a practical governance framework for clinical AI: the regulatory landscape as it currently stands, the specific categories of risk unique to clinical AI as distinct from other healthcare technology, the core principles a governance framework needs to encode, and a concrete organisational structure, a standing AI governance committee built around intake, validation, and monitoring, that a healthcare organisation can establish without waiting for a fully mature regulatory regime to force the issue reactively.

The paper also addresses the specific, distinct risk profile of generative AI tools now entering clinical documentation and patient communication workflows, sets out a practical validation and monitoring discipline for tools already in use, and closes with an implementation roadmap and a review of the pitfalls that most commonly undermine clinical AI governance efforts even when an organisation has genuinely committed to building the capability.

Why Clinical AI Governance Cannot Wait

Clinical AI differs from most other healthcare technology procurement in one critical respect: many of these tools continue to learn, or at minimum, their real-world performance can drift silently as the patient population, clinical workflows, or documentation patterns they were originally trained and validated on change over time. A sepsis prediction model validated on one hospital's patient population can perform meaningfully worse when deployed at another facility with a different case mix, different documentation habits, or a different distribution of comorbidities, and that degradation is not something a standard IT change-control process, built around software version releases and configuration changes, is designed to catch.

The absence of formal governance is not a neutral or default-safe position. Every clinical AI tool already in active use is making an implicit set of decisions about which patients it flags as high-risk and which it does not, and without a governance process actively monitoring those decisions, no one in the organisation may actually know, with any confidence, what those decisions are, whether they are being tracked against real outcomes, or who is accountable if the tool contributes to patient harm. Waiting for a regulatory mandate before building this governance capability means building it reactively, under pressure, after an incident or an unfavourable audit finding, rather than deliberately and on the organisation's own timeline.

The scale of exposure compounds as clinical AI adoption grows. A hospital piloting a single sepsis alert tool in one intensive care unit carries a bounded, containable risk. A health system running a dozen different AI-enabled tools across imaging, documentation, deterioration prediction, and prior authorisation, procured by different departments at different times with no shared governance process, carries a materially larger and less visible aggregate risk, precisely because no single function in the organisation has full visibility into the complete portfolio.

This paper is written for chief medical information officers, compliance leaders, clinical informatics teams, and health system boards who recognise that clinical AI governance is not a future problem to prepare for on a comfortable timeline, but a present gap between the AI tools already embedded in clinical workflows today and the oversight structure that should already exist around them.

It is worth being direct about why this gap exists in the first place, since understanding the cause shapes the right response. Clinical AI tools are frequently adopted through channels that bypass the organisation's traditional capital equipment or major software procurement process entirely: a department negotiates a pilot directly with a vendor, a clinical champion brings in a tool evaluated informally against a handful of cases, or a tool arrives bundled as a feature within a broader EHR module the organisation has already licensed for other reasons. None of these adoption paths naturally triggers the kind of cross-functional review that a major capital purchase would, which is precisely why so many organisations discover, once they actually look, that their real clinical AI footprint is considerably larger than anyone had previously tracked.

The Regulatory Landscape

The regulatory and standards landscape around clinical AI is genuinely still forming, but several concrete reference points already exist and are converging on a consistent set of expectations.

FDA Software as a Medical Device (SaMD) framework. The FDA regulates many AI-based clinical decision support tools as medical devices, with a distinct regulatory pathway, the predetermined change control plan, specifically designed for adaptive algorithms intended to update after initial deployment. Organisations deploying FDA-cleared AI tools inherit an ongoing obligation to operate them within the bounds of their cleared indication and intended use, not simply to treat the vendor's regulatory clearance as a substitute for the organisation's own local validation on its own patient population.

ONC HTI-1 rule. The Office of the National Coordinator's Health Data, Technology, and Interoperability rule requires certified health IT developers to provide defined transparency information, source data characteristics, development methodology, and known limitations, for AI and predictive decision support interventions embedded within certified electronic health record systems. This gives healthcare organisations a formal, standardised basis for evaluating a clinical AI tool before and during deployment, rather than relying solely on whatever documentation a vendor chooses to volunteer.

State-level activity. A number of states have introduced or already passed legislation addressing AI use specifically in healthcare decision-making, ranging from patient disclosure requirements, informing a patient when AI materially contributed to a clinical decision affecting their care, to specific restrictions on AI use in utilisation review and prior authorisation determinations. This regulatory landscape is genuinely still actively forming, and organisations operating across multiple states should expect continued change over the coming several years rather than a stable baseline to plan permanently around.

Professional and accreditation bodies. The Joint Commission and a number of specialty societies have begun issuing formal guidance on responsible AI use in clinical settings, and this guidance is converging, across organisations that otherwise have quite different mandates, on the same core set of expectations: documented human oversight at the point of clinical use, documented validation before and during deployment, and ongoing, active performance monitoring rather than a one-time approval.

The consistent pattern across every one of these regulatory and accreditation sources is a shift from oversight understood as a one-time approval event towards oversight understood as a continuous, monitored obligation, mirroring, in a different clinical domain, the same shift already underway in credentialing and quality governance more broadly across healthcare.

Organisations should also expect this landscape to keep evolving, and evolving faster than most healthcare regulatory domains typically do, given how quickly generative AI capability itself is advancing. A governance framework built today needs to be designed for ongoing revision as new guidance emerges, rather than treated as a fixed compliance checklist that, once completed, requires no further attention. This is one of the clearest arguments for building a standing committee rather than a one-time policy document: a committee can absorb new regulatory guidance as it emerges, where a static policy cannot.

Categories of Clinical AI Risk

Clinical AI carries several distinct categories of risk that a general-purpose IT governance process is not designed to anticipate or catch, and a clinical AI governance framework needs to address each explicitly.

• Model bias and equity. A model trained on a patient population that does not adequately reflect the deploying organisation's own demographics can systematically under-predict or over-predict risk for specific patient subgroups, a well-documented failure mode across several widely publicised clinical AI incidents in recent years. This risk is not hypothetical or rare; it is a predictable consequence of deploying a model outside the population characteristics it was actually trained and validated on, and it frequently does not appear in aggregate performance metrics, only becoming visible when performance is examined separately across relevant patient subgroups.
• Automation bias and over-reliance. Clinicians presented with a confident-sounding AI recommendation, particularly one presented with a precise-looking numerical risk score, can defer to it even in situations where their own independent clinical judgement would otherwise diverge, a tendency that becomes more pronounced under time pressure and high clinical workload. This erodes exactly the human oversight the tool was intended to support rather than replace, and it is a risk that tends to grow, not shrink, as clinicians become more accustomed to and trusting of a given tool over time.
• Silent performance drift. A model's real-world accuracy can degrade gradually as the patient population it serves, the clinical protocols surrounding its use, or the underlying documentation practices in the EHR shift over time, all without producing any obvious signal that would prompt a review, unless the organisation has an active, ongoing monitoring process specifically designed to catch this kind of gradual degradation rather than only checking performance once at initial deployment.
• Generative AI-specific risk. Large language model-based tools now used for clinical documentation assistance and patient-facing communication carry a distinct risk of confident, plausible-sounding fabrication, a risk profile meaningfully different from the more statistically predictable failure modes of earlier, narrower predictive models. Many existing clinical AI validation processes, designed around the failure modes of predictive scoring models, were not built to catch this specific kind of error, and organisations deploying generative tools need a validation approach that accounts for it directly.
• Accountability gaps. When a clinical AI tool contributes to an adverse patient outcome, unclear or absent governance can leave genuinely open questions about where responsibility sits, with the vendor who built the tool, the organisation that deployed it, or the individual clinician who acted on its output. These are questions far better resolved in advance, in a written governance policy the organisation has already adopted, than argued for the first time in the aftermath of an actual incident, under legal and regulatory pressure and with much less room to reach a considered answer.
• Vendor dependency and discontinuation risk. A clinical workflow that comes to depend on a specific AI tool's availability carries a distinct operational risk if that vendor discontinues the product, is acquired, or materially changes its pricing or terms. Governance frameworks should require a documented fallback clinical process for any AI tool embedded deeply enough into a workflow that its sudden unavailability would meaningfully disrupt patient care, so that a vendor business decision never becomes an unplanned patient safety event.

Core Principles of Responsible AI Governance

A small number of core principles, consistently reflected across the regulatory guidance and professional standards reviewed in this paper, should underpin any clinical AI governance framework.

• Human oversight is a design requirement, not an afterthought. Every clinical AI tool should have a clearly defined point in the clinical workflow at which a human clinician reviews and retains the ability to override its output before that output affects patient care. This oversight point needs to be built directly into the workflow design itself, not left to individual clinician discretion or assumed to happen informally simply because a human is nominally in the loop somewhere in the process.
• Transparency and explainability, proportionate to clinical risk. Higher-stakes clinical decisions, those with more significant consequences if the AI recommendation is wrong, warrant a correspondingly higher bar for the tool being able to explain its underlying reasoning in terms a clinician can actually evaluate and act on, not simply a bare confidence score or risk percentage with no accompanying rationale.
• Validation before deployment, on the organisation's own data. A vendor's published validation study, however methodologically rigorous in its own right, is not a substitute for confirming that the tool performs acceptably on the specific patient population it will actually be used on at the deploying organisation. Local validation is the step most frequently skipped under time or resource pressure, and it is also the step most directly correlated with catching population-mismatch problems before they affect real patients.
• Ongoing monitoring after deployment. Initial validation, however thorough, is a starting point rather than an endpoint. Performance needs to be actively tracked against real-world clinical outcomes on a defined, documented cadence for as long as the tool remains in active clinical use, not simply reviewed once at go-live and then assumed to remain stable indefinitely.
• Clear, named accountability. A specific named owner, whether an individual role or a standing committee, should be formally accountable for each clinical AI tool in active use, with the explicit, documented authority to pause or fully withdraw that tool from clinical use if performance concerns emerge, rather than accountability being diffused across departments to the point that no one function can act decisively when a concern is raised.

A Practical Governance Framework

The practical expression of these five principles is a standing AI governance committee with three core, clearly defined responsibilities: intake, validation, and monitoring.

Intake. No clinical AI tool, whether procured through the organisation's formal purchasing process or introduced informally at the department level by a clinical champion, should enter routine clinical use without passing through a defined intake process. That process should document, at minimum: what specific clinical problem the tool addresses, what data it was originally trained and validated on, its FDA regulatory status if applicable, and precisely what human oversight point is built into its intended clinical use.

Validation. Before deployment, and before any material update to an already-deployed tool, the governance committee, or a delegated technical subgroup with the relevant clinical and data science expertise, validates the tool's performance directly against the organisation's own patient population, not solely against the vendor's published results from a different population. This validation should be documented in enough detail that it could be presented to a surveyor or auditor as evidence of a genuine, substantive review rather than a pro forma approval.

Monitoring. Once deployed, each tool is assigned a monitoring cadence appropriate to its clinical risk level, with higher-risk tools reviewed more frequently than lower-risk ones, against a defined set of metrics: accuracy, false positive and false negative rates, and equity metrics examined across relevant patient subgroups where feasible, together with a documented escalation path specifying what happens if performance falls outside acceptable, pre-defined bounds.

This committee structure should include, at minimum, clinical representation from the specialties most affected by the tools under its purview, data science or clinical informatics expertise capable of interpreting model performance data critically, compliance representation familiar with the regulatory landscape described earlier in this paper, and IT representation responsible for the technical integration and monitoring infrastructure itself.

The committee's charter should also specify explicitly how it interacts with existing governance bodies the organisation already has in place, particularly the pharmacy and therapeutics committee where AI tools touch medication decisions, and the quality and patient safety committee where AI tools touch clinical outcomes directly. Duplicating oversight across multiple committees wastes scarce clinical time; the more effective pattern is for the AI governance committee to own the AI-specific technical review, while feeding its findings into the existing clinical governance structure the organisation already has, rather than creating an entirely parallel reporting line that competes for the same clinical leadership attention.

Validation, Monitoring, and Drift Detection

Validation should be treated as an ongoing organisational discipline rather than a one-time gate passed at deployment. Several practical steps make this concrete rather than aspirational.

• Establish a local baseline before go-live. Measure the tool's actual performance on the organisation's own recent patient data before it is used to inform any live clinical decision, so that any later performance change has a genuine local baseline to be measured against, rather than only the vendor's original validation figures from a different population.
• Define the metrics that actually matter for the specific clinical use case. Sensitivity and specificity are rarely equally important for a given clinical application; a sepsis screening tool and a documentation-summarisation tool warrant different primary metrics, and the governance committee should specify, in writing, which metrics matter most for each tool under its purview before that tool goes live.
• Schedule periodic re-validation, not only reactive review. Particularly after any material change to the organisation's patient population, its clinical protocols, or the underlying EHR configuration a given tool depends on for its inputs, since any of these changes can independently affect a model's real-world accuracy even when the model itself has not been altered by the vendor.
• Build a fast, accessible escalation path for frontline clinical observation. Clinicians who notice a tool behaving in a way that does not match their own clinical judgement are frequently the earliest available signal of genuine performance drift, well before that drift becomes visible in aggregate performance metrics reviewed on a quarterly cycle. A governance framework that makes this kind of frontline reporting easy, and visibly acts on it, catches problems considerably earlier than one that relies solely on scheduled, retrospective metric review.
• Document every validation and monitoring cycle, not only the outcome. A governance committee that can produce, on request, a clear record of what was measured, when, against what baseline, and what was concluded, is in a materially stronger position during a survey or an audit than one that can only assert, without documentation, that monitoring generally occurs. This documentation discipline also protects the organisation and its clinicians directly in the event a tool's output is later scrutinised in connection with an adverse outcome, since it demonstrates the governance process was genuinely active rather than nominal.

Implementation Roadmap

Organisations building clinical AI governance capability from a standing start can follow a sequenced, five-phase approach.

Phase one, Inventory. Catalogue every clinical AI tool currently in use across the organisation, explicitly including tools introduced informally at the department level outside any formal procurement process, since a governance framework cannot govern a tool it does not know exists. This inventory phase alone frequently surfaces a materially larger AI footprint than compliance or IT leadership had previously assumed.

Phase two, Committee formation. Establish the standing AI governance committee described earlier, with clinical, data science, compliance, and IT representation, and a clearly written charter defining its intake, validation, and monitoring authority, including its explicit authority to pause or withdraw a tool from clinical use.

Phase three, Retroactive review. Run every tool identified during the phase one inventory through the intake and validation process retroactively, prioritising the highest clinical-risk and highest-usage-volume tools first, since these carry the largest aggregate exposure if a problem exists that has not yet been caught.

Phase four, Forward process. Establish the intake process as a mandatory, non-optional gate for any new clinical AI tool going forward, with clear, actively communicated guidance to both clinical staff and procurement teams about exactly how to route a newly proposed tool through the process before it is deployed.

Phase five, Ongoing monitoring cadence. Establish the recurring monitoring schedule for every deployed tool, with committee review of monitoring results built into a defined, standing cycle, and a documented, tested process for escalation whenever a tool's performance falls outside its defined acceptable bounds.

As with the credentialing monitoring capability described in the companion paper in this series, organisations should expect this full sequence to take several months, reflecting the genuine work of cataloguing an existing, often informally assembled AI footprint and building committee capability and clinical trust in the new process, rather than any unusual technical difficulty in the governance framework itself.

Common Pitfalls

Several recurring mistakes account for a disproportionate share of clinical AI governance efforts that fail to produce lasting oversight, even at organisations that have genuinely committed resources to building the capability.

• Treating vendor FDA clearance as a substitute for local validation. Regulatory clearance confirms safety and efficacy for the population studied during the clearance process, not necessarily for the deploying organisation's own, potentially quite different, patient population.
• Building a governance policy with no enforcement mechanism. A written policy that is not actively enforced simply allows tools to continue being adopted informally at the department level, entirely outside the intake process the organisation has formally adopted on paper.
• Monitoring only in aggregate. Aggregate performance metrics can look entirely acceptable while masking real equity problems that only become visible when performance is examined separately across specific patient subgroups.
• Treating governance as a one-time compliance exercise. Clinical AI governance is a standing organisational capability requiring ongoing staffing and sustained attention, not a project with a defined end date after which the committee can be safely disbanded.
• Underestimating generative AI's distinct risk profile. Applying the same validation approach developed for earlier, more statistically predictable predictive models to generative tools risks missing the confident-fabrication failure mode that is specific to large language model-based systems.

Conclusion

Clinical AI governance is not a future compliance obligation organisations can reasonably defer preparing for. For most healthcare organisations, it is a present gap between the AI tools already embedded in routine clinical workflows and the oversight structure that should already exist around them. The regulatory landscape, FDA's SaMD framework, ONC's HTI-1 transparency requirements, and a growing body of state-level legislative activity, is converging on a consistent, recognisable set of expectations: documented human oversight, validation on the organisation's own data rather than solely a vendor's published results, and ongoing, active performance monitoring rather than a one-time approval.

A standing governance committee built around intake, validation, and monitoring gives an organisation a defensible, evidence-based answer to the question every accreditor, regulator, and, in the event of an adverse outcome, plaintiff's attorney will eventually ask: how does the organisation know its clinical AI is working the way it believes it is, for the specific patients it is actually being used on, today, not merely at the point it was first deployed.